Figure 1From: A case report on efficacy of Abound™ for anti-EGFR antibody-associated skin disorder in metastatic colon cancerBefore and after images of AboundTMtreatment: face. (a) Before AboundTM was administered (CTCAE version 4.0: Grade 2). (b) After AboundTM was administered (CTCAE version 4.0: Grade 1). CTCAE, common terminology criteria for adverse events.Back to article page